Article Impact Level: HIGH Data Quality: STRONG Summary of Cardiovascular Research https://doi.org/10.1093/cvr/cvaf171 Dr. Mei Methawasin et al.
Points
- HFpEF is a widespread, life-threatening condition presenting significant treatment challenges, often linked to risk factors like obesity and hypertension that impair ventricular filling.
- Titin-based stiffness, regulated by RBM20, critically determines diastolic function and can be modulated to improve cardiac performance.
- Partial RBM20 inhibition in a mouse model improved diastolic function by increasing compliant titin isoforms and reducing left ventricular stiffness.
- This intervention preserved systolic performance and mitigated cardiac hypertrophy, even with ongoing systemic metabolic comorbidities present.
- Targeting titin stiffness with RBM20-ASOs offers a promising adjunctive therapeutic strategy for HFpEF, restoring function and preventing further organ damage.
Summary
Research has explored the therapeutic potential of RBM20 antisense oligonucleotides (ASOs) in a mouse model of heart failure with preserved ejection fraction (HFpEF), a prevalent and difficult-to-treat condition. This model, characterized by metabolic syndrome and comorbidities, was used to evaluate the effects of RBM20 inhibition on diastolic function without pre-existing titin or RBM20 defects. The study aimed to optimize ASO dosing and document its utility in cardiometabolic disease, which is known to contribute to cardiac inflammation, metabolic defects, and pathological remodeling that impairs ventricular filling.
The optimized RBM20-ASO dosing resulted in an approximate 50% inhibition of RBM20. This partial inhibition selectively increased compliant titin isoforms, leading to an improvement in diastolic function while preserving systolic performance. Specifically, the intervention was shown to reduce left ventricular stiffness, enhance cardiac relaxation, and mitigate cardiac hypertrophy. These improvements were observed despite the ongoing presence of systemic comorbidities in the mouse model, indicating the potential for therapeutic efficacy even in complex cardiometabolic environments.
In conclusion, these findings suggest that targeting titin stiffness through RBM20-ASOs represents a promising alternative or adjunctive therapeutic strategy for HFpEF. The approach can potentially restore cardiac function and prevent further organ damage. The study highlights the potential benefits of this intervention even in the context of phenotypic heterogeneity and unresolved systemic comorbidities, offering a novel avenue for treating a condition with significant unmet medical needs.
Link to the article: https://academic.oup.com/cardiovascres/advance-article/doi/10.1093/cvr/cvaf171/8286279?login=false
References
Methawasin, M., Meinke, S., Radke, M. H., Farman, G. P., Hourani, Z., Smith, J. E., Guo, W., Granzier, H., & Gotthardt, M. (2025). Rbm20 antisense oligonucleotides alleviate diastolic dysfunction in a mouse model of cardiometabolic heart failure (Hfpef). Cardiovascular Research, cvaf171. https://doi.org/10.1093/cvr/cvaf171
